핵의학 이미징 시장 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The nuclear medicine market reached USD 17.81 billion in 2025 and is projected to climb to USD 25.91 billion by 2030, reflecting a 7.78% CAGR and underscoring the sector's solid mid-decade momentum.

Demand gains stem from rapid clinical adoption of targeted radiopharmaceuticals, ongoing upgrades to hybrid PET/CT and SPECT/CT scanners, and new reimbursement rules that separate high-cost tracers from bundled imaging payments. Government-backed investments in replacement isotope reactors, the build-out of hospital-based cyclotrons, and artificial-intelligence workflow tools further widen addressable procedure volumes. At the same time, persistent shortages of molybdenum-99, rising equipment outlays, and a widening technologist talent gap temper near-term upside. Well-capitalized suppliers are responding with vertical integration strategies that link isotope production, generator distribution, and software-enabled scanners, positioning themselves to capture premium margins as therapeutic applications broaden. Taken together, innovation advances faster than structural constraints, sustaining the nuclear medicine market's long-run expansion trajectory.

Global Nuclear Imaging Market Trends and Insights

Rising Cancer and Cardiovascular Disease Incidence

Global oncology and cardiology case loads continue to climb, creating durable demand for both diagnostic imaging and therapeutic radiopharmaceuticals. FDA approval of Lu-177 PSMA-617 generated USD 1.04 billion in nine-month 2024 sales, validating precision oncology's commercial scale. Cardiology meanwhile benefits from flurpiridaz F-18, which delivers superior sensitivity over legacy SPECT perfusion scans and enables exercise-stress protocols. Procedure growth spreads beyond mature markets as emerging economies integrate nuclear medicine units into tertiary hospitals. Because the same radioisotope infrastructure serves both disease areas, volume expansion produces operating-leverage benefits that reinforce supplier profitability. Ongoing increases in life expectancy and lifestyle-driven risk factors point to sustained high procedure counts through the forecast horizon.

Rapid Adoption of Hybrid PET/CT and SPECT/CT Systems

Hybrid imaging unites functional tracer data with high-resolution anatomical detail in a single exam, improving lesion localization while lowering false-negative rates. PET procedure volumes jumped 12.2% year-on-year in 2024 and average scans per PET/CT system rose 8.2%, signaling both installed-base expansion and higher utilization. Next-generation total-body PET platforms shorten acquisition times to under one minute, cutting tracer dose and boosting patient throughput. SPECT/CT gains detector efficiency from cadmium-zinc-telluride crystals, supporting low-activity protocols that lower pharmacy costs. AI engines embedded in reconstruction software automate organ segmentation and attenuation correction, freeing technologists for higher-value tasks. Hospitals thus view platform upgrades as a route to superior diagnostic accuracy and faster return on capital, accelerating the replacement cycle.

Fragile Mo-99 and Other Isotope Supply Chains

October 2024 maintenance delays at Europe's Petten and Maria reactors cut Mo-99 deliveries by up to 100%, forcing clinics to postpone scans and ration generator activity. U.S. congressional hearings warned the nation remains vulnerable to similar disruptions, given its continuing reliance on imported technetium. While accelerator-based production pilots show promise, they cannot yet replace multi-curie reactor output. Such supply fragility raises procurement costs and complicates scan scheduling, constraining near-term nuclear medicine market growth.

Other drivers and restraints analyzed in the detailed report include:

1. Regulatory Approvals of Novel PSMA- and FAPI-Based Tracers
2. Government Investments in Isotope-Production Reactors
3. High Capital Cost and Patchy Reimbursement

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Radioisotopes held 76.23% of the nuclear medicine market share in 2024, reflecting their role as indispensable consumables across every imaging and therapeutic workflow . The segment is forecast to post an 8.17% CAGR, outpacing equipment sales as tracer approvals multiply and theranostics gain traction. SPECT isotopes such as technetium-99m maintain procedure leadership, accounting for roughly 80% of global nuclear scans, yet remain exposed to reactor-outage risk. PET isotopes grow faster as F-18 FDG expands beyond oncology into cardiology and infection imaging, while novel F-18 FAPI agents penetrate difficult-to-image malignancies. Alpha-emitting isotopes enter early commercial roles in neuroendocrine and prostate cancer, though low production volumes constrain revenue scale.

Equipment sales benefit from hybrid upgrade cycles and AI-driven workflow features. Total-body PET platforms, priced at the system premium, enable eyes-to-thigh coverage within minutes, significantly raising department capacity. SPECT/CT gains detector sensitivity improvements that permit pediatric and renal protocols with reduced radiation burden. PET/MRI remains a niche for neuro-oncology research owing to high acquisition costs and integration complexity. Hospitals increasingly co-purchase cyclotrons to secure tracer supply, bundling financing packages that spread capital repayment across equipment, isotope contracts, and software maintenance. Together, these dynamics keep the nuclear medicine market size anchored by radioisotope volume growth even as hardware values advance steadily.

The Nuclear Medicine Market Report is Segmented by Product (Equipment: PET/CT Scanners, SPECT/CT Scanners, PET/MRI Scanners; Radioisotopes: SPECT and PET Radioisotopes), Application (SPECT and PET Applications), End User (Hospitals, Diagnostic Imaging Centres, Academic & Research Institutes), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America led the nuclear medicine market with 42.23% share in 2024, supported by the world's largest fleet of PET/CT scanners, robust payor coverage, and a deep pipeline of FDA-cleared tracers. CMS's 2025 radiopharmaceutical payment carve-out above USD 630 removes a key deterrent to high-cost agents, encouraging hospitals to adopt F-18, Ga-68, and Cu-64 tracers for oncology, cardiology, and infection imaging. The U.S. also houses multiple cyclotron clusters and emerging accelerator production trials for Mo-99, aiming to reduce import dependence. Canada contributes specialized isotope production through the McMaster and TRIUMF facilities yet continues to rely on cross-border generator flows after the Chalk River reactor retirement.

Europe ranks second, balancing coordinated health systems with sustained public investment in isotope infrastructure. The EUR 2.2 billion Pallas reactor project secures long-term technetium supply and supports therapeutic isotope diversification. France positions itself at the forefront of alpha-therapy manufacturing via Orano Med's thorium-228 plant, projected to supply 100,000 lead-212 doses annually post-2034. Regulatory agility is on display with U.K. MHRA approval of the first technetium-PSMA product, illustrating a willingness to extend tracer innovation beyond PET-dominant pathways. However, periodic reactor outages and varying national reimbursement tariffs produce patchwork market conditions across the bloc.

Asia-Pacific delivers the fastest regional growth at a 9.23% CAGR through 2030, spurred by large unmet diagnostic needs, rising oncology prevalence, and aggressive government backing for isotope self-sufficiency. China operates nearly 1,200 nuclear medicine departments and aims to double service capacity by 2035 under its medical-isotope development blueprint. Japan blends advanced device engineering with a growing radiopharmaceutical export platform, bolstered by GE HealthCare's takeover of Nihon Medi-Physics. India and South Korea prioritize cyclotron deployments to support burgeoning PET activity and medical-tourism demand. Australia builds redundancy into Mo-99 supply through the ANSTO OPAL reactor. Across the region, regulatory harmonization efforts and workforce-training initiatives seek to keep pace with rapid equipment installation, shaping Asia-Pacific into the next demand engine for the nuclear medicine market.

List of Companies Covered in this Report:

1. GE HealthCare Technologies Inc.
2. Siemens Healthineers
3. Koninklijke Philips
4. Canon
5. United Imaging Healthcare Co., Ltd.
6. Cardinal Health
7. Curium Pharma
8. Bracco Imaging S.p.A.
9. Bayer
10. Novartis
11. Lantheus
12. BWX Technologies Inc. (Nordion)
13. Eckert & Ziegler SE
14. Jubilant Pharmova Ltd.
15. Telix Pharmaceuticals Ltd.
16. Clarity Pharmaceuticals Ltd.
17. Spectrum Dynamics Medical Inc.
18. MiE Medical Imaging Electronics GmbH
19. Digirad Corp.
20. SOFIE Biosciences Inc.
21. Isotope Technologies Garching GmbH
22. NTP Radioisotopes
23. CMR Naviscan

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 * Rising cancer & CVD incidence
  • 4.2.2 * Rapid adoption of hybrid PET/CT & SPECT/CT systems
  • 4.2.3 * Regulatory approvals of novel PSMA- & FAPI-based tracers
  • 4.2.4 * Government investments in isotope-production reactors
  • 4.2.5 * Decentralised hospital cyclotrons
  • 4.2.6 * AI-driven dose- and workflow optimisation
• 4.3 Market Restraints
  • 4.3.1 * Fragile Mo-99 and other isotope supply chains
  • 4.3.2 * High capital cost & patchy reimbursement
  • 4.3.3 * Shortage of certified nuclear-medicine technologists
  • 4.3.4 * Slow regulatory path for alpha-emitting therapeutics
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Product (Value)
  • 5.1.1 Equipment
    • 5.1.1.1 PET/CT Scanners
    • 5.1.1.2 SPECT/CT Scanners
    • 5.1.1.3 PET/MRI Scanners
  • 5.1.2 Radioisotopes
    • 5.1.2.1 SPECT Radioisotopes
    • 5.1.2.1.1 Technetium-99m (Tc-99m)
    • 5.1.2.1.2 Thallium-201 (Tl-201)
    • 5.1.2.1.3 Gallium-67 (Ga-67)
    • 5.1.2.1.4 Iodine-123 (I-123)
    • 5.1.2.1.5 Other SPECT Isotopes
    • 5.1.2.2 PET Radioisotopes
    • 5.1.2.2.1 Fluorine-18 (F-18)
    • 5.1.2.2.2 Rubidium-82 (Rb-82)
    • 5.1.2.2.3 Other PET Isotopes
• 5.2 By Application (Value)
  • 5.2.1 SPECT Applications
    • 5.2.1.1 Cardiology
    • 5.2.1.2 Neurology
    • 5.2.1.3 Thyroid
    • 5.2.1.4 Other SPECT Applications
  • 5.2.2 PET Applications
    • 5.2.2.1 Oncology
    • 5.2.2.2 Cardiology
    • 5.2.2.3 Neurology
    • 5.2.2.4 Other PET Applications
• 5.3 By End User (Value)
  • 5.3.1 Hospitals
  • 5.3.2 Diagnostic Imaging Centres
  • 5.3.3 Academic & Research Institutes
• 5.4 By Geography (Value)
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 South America
    • 5.4.4.1 Brazil
    • 5.4.4.2 Argentina
    • 5.4.4.3 Rest of South America
  • 5.4.5 Middle East and Africa
    • 5.4.5.1 GCC
    • 5.4.5.2 South Africa
    • 5.4.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 GE HealthCare Technologies Inc.
  • 6.3.2 Siemens Healthineers AG
  • 6.3.3 Koninklijke Philips N.V.
  • 6.3.4 Canon Medical Systems Corp.
  • 6.3.5 United Imaging Healthcare Co., Ltd.
  • 6.3.6 Cardinal Health Inc.
  • 6.3.7 Curium Pharma
  • 6.3.8 Bracco Imaging S.p.A.
  • 6.3.9 Bayer AG
  • 6.3.10 Novartis AG (Advanced Accelerator Applications)
  • 6.3.11 Lantheus Holdings Inc.
  • 6.3.12 BWX Technologies Inc. (Nordion)
  • 6.3.13 Eckert & Ziegler SE
  • 6.3.14 Jubilant Pharmova Ltd.
  • 6.3.15 Telix Pharmaceuticals Ltd.
  • 6.3.16 Clarity Pharmaceuticals Ltd.
  • 6.3.17 Spectrum Dynamics Medical Inc.
  • 6.3.18 MiE Medical Imaging Electronics GmbH
  • 6.3.19 Digirad Corp.
  • 6.3.20 SOFIE Biosciences Inc.
  • 6.3.21 Isotope Technologies Garching GmbH
  • 6.3.22 NTP Radioisotopes SOC
  • 6.3.23 CMR Naviscan (Gamma Medica Inc.)

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment